High Quality Proteins Supplier
With over 20 years of experience in peptide synthesis, we have advanced peptide synthesis instruments, professional team, and extensive expertise in peptide synthesis and purification processes. Our advanced peptide synthesis platform and quality control system work together to provide clients with high-quality products.
In the rapidly evolving field of drug discovery, innovation and precision are paramount. Our company, through its proprietary KPDS™ platform (KS-V Peptide Discovery Services Platform), stands at the forefront of peptide drug discovery. The KPDS™ platform is internationally recognized for its advanced capabilities in peptide innovation, providing a one-stop, customized solution for drug development. This platform is designed to streamline the drug discovery process, offering flexibility in product forms and service models to accelerate the advancement of our clients' projects.
The core strength of KPDS™ lies in its ability to support a wide range of applications. Our services encompass not only the development of peptide drugs but also extend to disease diagnostics, health products, and radiolabeled drugs (RDCs). We also specialize in small molecule-based peptide drug conjugates (PDCs) and multifunctional peptide conjugates, addressing the diverse needs of modern medicine. The platform's unique approach allows for the precise and efficient development of therapeutic candidates, enabling faster and more accurate targeting of diseases.
At the heart of our operations is the commitment to driving innovation in peptide drug discovery. The KPDS™ platform is built to meet the complex challenges of today's drug discovery landscape, offering tailored solutions that enhance the speed and effectiveness of the drug development process. By leveraging our proprietary technology, we empower our clients to push the boundaries of what is possible in medical research, ultimately contributing to the development of groundbreaking therapies that improve patient outcomes globally.
Our dedication to innovation and excellence makes KPDS™ a pivotal player in the field, supporting the discovery and development of next-generation therapeutics that address unmet medical needs.
Introduction: Peptides, as nature’s molecular artisans, offer a treasure trove of therapeutic potential, from combating diseases to advancing biotechnological applications. The pursuit of discovering novel peptides is a captivating journey into the intricate world of molecular design and function. This article delves into the strategies and advancements in peptide discovery, highlighting its pivotal role in shaping modern medicine and biotechnology.
Understanding Peptide Discovery: Peptide discovery encompasses a multifaceted approach that integrates computational modeling, combinatorial chemistry, and innovative screening techniques. Computational tools play a crucial role in predicting peptide structures, interactions, and bioactivities, guiding researchers in designing custom peptides with desired properties. Combinatorial chemistry techniques enable the synthesis of vast peptide libraries, providing a diverse pool for screening.
Screening and Selection: High-throughput screening methods accelerate the identification of bioactive peptides from large libraries. Techniques such as phage display, yeast two-hybrid systems, and bacterial display enable the rapid screening of peptide candidates based on their binding affinity, specificity, and functional activity. Moreover, advances in microfluidics and automation have streamlined the screening process, enhancing efficiency and throughput.
Targeted Applications: Peptides exhibit remarkable versatility in therapeutic applications, ranging from antimicrobial agents and anticancer drugs to peptide-based vaccines and drug delivery systems. By targeting specific molecular pathways or cellular receptors, therapeutic peptides offer precise and tailored treatment options with reduced off-target effects. Additionally, peptide-based biomaterials hold promise for tissue engineering, regenerative medicine, and diagnostics, opening new frontiers in healthcare innovation.
Emerging Trends: The field of peptide discovery continues to evolve with emerging trends such as de novo peptide design, peptide-drug conjugates, and peptide-based therapeutics for personalized medicine. De novo design approaches leverage machine learning algorithms and structural biology insights to engineer peptides with enhanced stability, specificity, and bioactivity. Peptide-drug conjugates combine the targeting ability of peptides with the therapeutic payload of small molecules, enabling targeted drug delivery and improved efficacy.
Challenges and Future Directions: Despite significant progress, peptide discovery faces challenges such as peptide stability, bioavailability, and immunogenicity. Addressing these hurdles requires innovative strategies in peptide engineering, formulation, and delivery. Future directions in peptide discovery involve harnessing synthetic biology techniques, exploring peptide mimetics, and leveraging interdisciplinary collaborations to accelerate translation from bench to bedside.
Conclusion: Peptide discovery epitomizes the synergy between scientific inquiry and technological innovation, offering a rich tapestry of molecular solutions to address unmet medical needs and societal challenges. By unraveling nature’s molecular gems, researchers continue to unlock the therapeutic potential of peptides, shaping the landscape of modern medicine and biotechnology.
In essence, peptide discovery transcends the boundaries of traditional drug development, heralding a new era of precision medicine and molecular therapeutics.
In 2023, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) hit a significant milestone, approving 55 new drugs, an increase of nearly 50% from last year and second only to the all-time high of 2018 . This number highlights the innovative trend in the pharmaceutical field and demonstrates the industry’s great success in different treatment areas. What is particularly eye-catching is that among the new drugs approved by the FDA in 2023, antibody drugs occupy a prominent position, including China’s domestic PD-1 monoclonal antibodies, which brings new hope to the medical community.
Among these 55 new drugs, oncology once again became the most approved treatment area, fully reflecting the medical community’s in-depth research on cancer treatment. At the same time, the fields of neurology and infectious diseases have also been recognized by the FDA, providing more treatment options for patients. The emergence of new drugs will promote the rapid development of medical technology and further promote progress in the health field.
It is worth mentioning that 2023 has also become a year of significant progress in the field of rare diseases, providing patients with new treatment options. Pfizer performed well this year. Not only did it become the company with the most approvals, it also launched a number of highly anticipated new products, covering multiple disease fields such as tumors, immunity, infection, and the nervous system.
In this dynamic year of medical innovation, it is worth noting that there are 6 new drugs that belong to the peptide drug category. They are:
1.Daybue (Trofinetide, Trofinetide)
2.Rezzayo (Rezafungin, Rezafungin)
3.Paxlovid (nirmatrelvir&ritonavir)
4.Posluma (flotufolastat F 18)
5.Aphexda (Motixafortide, motixafortide)
6.Zilbrysq(Zilucoplan)
The approval of new drugs this year witnessed the joint efforts of medical research and industrial development, providing patients with more innovative treatments and writing a new chapter for building a healthier future.
| No. | Drug Name | Active Ingredient | Approval Date | FDA-approved use on approval date* |
| 55 | Wainua | eplontersen | 12/21/2023 | To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis |
| 54 | Filsuvez | birch triterpenes | 12/18/2023 | To treat wounds associated with dystrophic and junctional epidermolysis bullosa |
| 53 | Fabhalta | iptacopan | 12/5/2023 | To treat paroxysmal nocturnal hemoglobinuria |
| 52 | Ogsiveo | nirogacestat | 11/27/2023 | To treat adults with progressing desmoid tumors who require systemic treatment |
| 51 | Truqap | capivasertib | 11/16/2023 | To treat breast cancer that meets certain disease criteria |
| 50 | Ryzneuta | efbemalenograstim alfa-vuxw | 11/16/2023 | To treat neutropenia |
| 49 | Augtyro | repotrectinib | 11/15/2023 | To treat ROS1-positive non-small cell lung cancer |
| 48 | Defencath | taurolidine, heparin | 11/15/2023 | To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter |
| 47 | Fruzaqla | fruquintinib | 11/8/2023 | To treat refractory, metastatic colorectal cancer |
| 46 | Loqtorzi | toripalimab-tpzi | 10/27/2023 | To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies |
| 45 | Omvoh | mirikizumab-mrkz | 10/26/2023 | To treat ulcerative colitis |
| 44 | Agamree | vamorolone | 10/26/2023 | To treat Duchenne muscular dystrophy |
| 43 | Bimzelx | bimekizumab | 10/17/2023 | To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy |
| 42 | Zilbrysq | zilucoplan | 10/17/2023 | To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive |
| 41 | Velsipity | etrasimod | 10/12/2023 | To treat moderately to severely active ulcerative colitis in adults |
| 40 | Rivfloza | nedosiran | 9/29/2023 | To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function |
| 39 | Pombiliti | cipaglucosidase alfa-atga | 9/28/2023 | To treat late-onset Pompe disease |
| 38 | Exxua | gepirone | 9/22/2023 | To treat major depressive disorder |
| 37 | Ojjaara | momelotinib | 9/15/2023 | To treat intermediate or high-risk myelofibrosis in adults with anemia |
| 36 | Aphexda | motixafortide | 9/8/2023 | To use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma |
| 35 | Veopoz | pozelimab-bbfg | 8/18/2023 | To treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease |
| 34 | Sohonos | palovarotene | 8/16/2023 | To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva |
| 33 | Elrexfio | elranatamab-bcmm | 8/14/2023 | To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy |
| 32 | Talvey | talquetamab-tgvs | 8/9/2023 | To treat adults with relapsed or refractory multiple myeloma who have received at least four prior therapies |
| 31 | Izervay | avacincaptad pegol | 8/4/2023 | To treat geographic atrophy secondary to age-related macular degeneration |
| 30 | Zurzuvae | zuranolone | 8/4/2023 | To treat postpartum depression |
| 29 | Xdemvy | lotilaner | 7/25/2023 | To treat Demodex blepharitis |
| 28 | Vanflyta | quizartinib | 7/20/2023 | To use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria |
| 27 | Beyfortus | nirsevimab-alip | 7/17/2023 | To prevent respiratory syncytial virus (RSV) lower respiratory tract disease |
| 26 | Ngenla | somatrogon-ghla | 6/27/2023 | To treat growth failure due to inadequate secretion of endogenous growth hormone |
| 25 | Rystiggo | rozanolixizumab-noli | 6/26/2023 | To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive |
| 24 | Litfulo | ritlecitinib | 6/23/2023 | To treat severely patchy hair loss |
| 23 | Columvi | glofitamab-gxbm | 6/15/2023 | To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy |
| 22 | Inpefa | sotagliflozin | 5/26/2023 | To treat heart failure |
| 21 | Posluma | flotufolastat F 18 | 5/25/2023 | To use with positron emission tomography imaging in certain patients with prostate cancer |
| 20 | Paxlovid | nirmatrelvir, ritonavir | 5/25/2023 | To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19 |
| 19 | Xacduro | sulbactam, durlobactam | 5/23/2023 | To treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex |
| 18 | Epkinly | epcoritamab-bysp | 5/19/2023 | To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy |
| 17 | Miebo | perfluorhexyloctane | 5/18/2023 | To treat signs and symptoms of dry eye disease |
| 16 | Veozah | fezolinetant | 5/12/2023 | To treat moderate to severe hot flashes caused by menopause |
| 15 | Elfabrio | pegunigalsidase alfa-iwxj | 5/9/2023 | To treat confirmed Fabry disease |
| 14 | Qalsody | tofersen | 4/25/2023 | To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation |
| 13 | Joenja | leniolisib | 3/24/2023 | To treat activated phosphoinositide 3-kinase delta syndrome |
| 12 | Rezzayo | rezafungin | 3/22/2023 | To treat candidemia and invasive candidiasis |
| 11 | Zynyz | retifanlimab-dlwr | 3/22/2023 | To treat metastatic or recurrent locally advanced Merkel cell carcinoma |
| 10 | Daybue | trofinetide | 3/10/2023 | To treat Rett syndrome |
| 9 | Zavzpret | zavegepant | 3/9/2023 | To treat migraine |
| 8 | Skyclarys | omaveloxolone | 2/28/2023 | To treat Friedrich’s ataxia |
| 7 | Filspari | sparsentan | 2/17/2023 | To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression |
| 6 | Lamzede | velmanase alfa-tycv | 2/16/2023 | To treat non-central nervous system manifestations of alpha-mannosidosis |
| 5 | Jesduvroq | daprodustat | 2/1/2023 | To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months |
| 4 | Orserdu | elacestrant | 1/27/2023 | To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy |
| 3 | Jaypirca | pirtobrutinib | 1/27/2023 | To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor |
| 2 | Brenzavvy | bexagliflozin | 1/20/2023 | To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise |
| 1 | Leqembi | lecanemab-irmb | 1/6/2023 | To treat Alzheimer’s disease |